It's schedule 1 here in the US, which makes it ridiculously difficult to get/test/research to prove whether or not it truly belongs in that category. The research is promising but as others have stated the risk/benefit ratio MAY not bear fruit. We have a difficult enough time getting our regulators to take cannabis off the schedule 1 list despite billions of doses being used. Tough times for a potentially useful compound ripe for investogation.